AVDL - Avadel to 'vigorously' defend against patent violations claims filed by Jazz

Yesterday, Jazz Pharmaceuticals (JAZZ) filed a complaint in Delaware federal court against Avadel Pharmaceuticals (AVDL) regarding an alleged infringement of five patents linked to the company’s blockbuster therapy Xyrem.The FDA application sought by Avadel to market its narcolepsy drug, FT218 violated the patents according to Jazz. Both drugs use the same active ingredient sodium oxybate."We plan to defend our innovations and continue to provide therapies and support for our patients," Reuters quoted Jazz spokeswoman Kristin Bhavnani as saying in an email.In response to allegations, Avadel says that the company intends strongly defend against Jazz’s patent claims.“The Company believes it has defenses to any related causes of action and plans to vigorously pursue these defenses,” Avadel maintained in a regulatory submission filed today.In 2020, Xyrem generated $1.7B net product sales for Jazz representing 74% of its total net product sales.

For further details see:

Avadel to 'vigorously' defend against patent violations claims filed by Jazz